Sydney, Feb 14, 2007 (ABN Newswire) - Neuren Pharmaceuticals Limited (ASX: NEU) - Further Validation of NNZ-2566 as a Traumatic Brain Injury Treatment - Mr David Clarke, CEO; Boardroomradio is pleased to announce that Neuren Pharmaceuticals Limited (ASX: NEU) has published an audio file. The following presentation "Further Validation of NNZ-2566 as a Traumatic Brain Injury Treatment" is now available as an instant audio download to your computer. You may also transfer this information to your listening device as an IPod podcast.
The BRR service is based on streaming audio sent in compressed form over the internet and displayed as it arrives. You do not have to wait for the whole file to be downloaded before you can hear it, instead the media is sent in a continuous stream and is played immediately as it reaches your computer. Please note that during live broadcasts there can be a delay of approximately 1-2 minutes, depending on traffic through your Internet Service Provider.
Neuren Pharmaceuticals is a biopharmaceutical company developing novel therapeutics in the fields of brain injury, neurological diseases and conditions, and metabolic disorders. The Neuren portfolio comprises eight product families targeting markets with large unmet needs and limited competition. Neuren has three clinical-stage molecules - Glypromate(R), MotivaTM and NNZ-2566 -focused on a range of acute and chronic neurological conditions. For more information visit: http://www.neurenpharma.com
About Boardroomradio
Sydney-based Boardroomradio (BRR) is an Investor Relations multi-media portal delivering audio webcasts to the investment community, including brokers, fund managers, analysts, and private investors.
News 
